Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PLSE | CLUSTER | bullish | 7/10 | Two insiders at Pulse Biosciences, including CEO Paul LaViolette and director/10% owner Robert Duggan, made open-market | May 15, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | CEO Roger Jeffs and Director Stephen Bloch sold a combined $5.15M in open-market sales over a 5-day window, representing | May 15, 2026 |
| PTCT | CLUSTER | neutral | 2/10 | Two PTCT insiders, including CEO Matthew Klein, sold a combined ~$115K in open-market sales within a week of the company | May 15, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Four UTHR insiders (CEO, CFO, EVP, Director) sold a total of ~$1.04M in open-market sales over a 7-day window following | May 15, 2026 |
| RPRX | CLUSTER | neutral | 3/10 | Two insiders at Royalty Pharma sold a combined $888K in open-market sales on May 14, 2026, following the company's Q1 ea | May 15, 2026 |
| KPTI | CLUSTER | bearish | 6/10 | Six Karyopharm executives, including the CEO and C-suite, sold a total of $35K in open-market shares on May 14, 2026, on | May 15, 2026 |
| INSM | CLUSTER | neutral | 3/10 | Two C-suite insiders (CMO and CLO) sold a total of ~$981K worth of INSM shares, representing a trivial 0.004% of the $25 | May 15, 2026 |
| VCEL | CLUSTER | neutral | 2/10 | Vericel Corp insiders sold ~$459K in open-market transactions over the past week, representing a trivial 0.027% of the $ | May 15, 2026 |
| KPTI | CLUSTER | neutral | 3/10 | Five Karyopharm insiders, including the CEO and C-suite, sold a total of $31K in open-market sales on May 14, 2026, the | May 15, 2026 |
| KPTI | CLUSTER | bearish | 6/10 | Karyopharm's CEO, CAO, and EVP/CLO sold a total of $23K in open-market shares on May 14, 2026, the same day the company | May 15, 2026 |
| LGND | CLUSTER | neutral | 3/10 | Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligan | May 14, 2026 |
| PTGX | CLUSTER | neutral | 4/10 | Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director | May 14, 2026 |
| STTK | CLUSTER | neutral | 3/10 | Two senior executives at Shattuck Labs (CMO and CTO) sold a combined $212K in open-market shares on May 12, 2026, one we | May 14, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | A cluster of insider sales at United Therapeutics (UTHR) totaling $1.72M occurred within 8 days of a Q1 2026 earnings re | May 14, 2026 |
| LODE | CLUSTER | bullish | 6/10 | Two Comstock Inc. insiders, including CEO Corrado DeGasperis and Director Steven Yu-Tsung Pei, made open-market purchase | May 14, 2026 |
| RCKT | CLUSTER | neutral | 3/10 | Rocket Pharmaceuticals CEO Gaurav Shah sold $10K worth of shares and another insider sold $68K, totaling $78K in open-ma | May 14, 2026 |
| MNKD | CLUSTER | neutral | 3/10 | Two insiders at MannKind Corp made open-market sales totaling $66K (0.007% of market cap) on May 12, 2026, one week afte | May 13, 2026 |
| ANIP | CLUSTER | neutral | 4/10 | A cluster of insider sales at ANI Pharmaceuticals, led by CEO Nikhil Lalwani selling $4.27M worth of shares, follows a s | May 13, 2026 |
| ARQT | CLUSTER | neutral | 3/10 | Four Arcutis insiders sold a total of $283K in open-market sales over a one-week window, including the CFO and three oth | May 13, 2026 |
| ODTX | CLUSTER | bullish | 7/10 | Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market purchases totaling | May 13, 2026 |
| INSM | CLUSTER | neutral | 3/10 | Insmed's CEO and CMO sold a combined $1.27M in stock within a week of a strong Q1 2026 earnings beat (revenue up 230% Yo | May 13, 2026 |
| GNLX | CLUSTER | neutral | 2/10 | Two insiders at Genelux Corp sold a total of $9K in open-market sales on May 11, 2026, including the CEO and Head of Reg | May 12, 2026 |
| PTGX | CLUSTER | neutral | 5/10 | CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a week of PTGX reporting | May 12, 2026 |
| HOWL | CLUSTER | bearish | 6/10 | Two insiders at Werewolf Therapeutics sold a total of $299K in open-market sales over a 7-day window, representing ~0.9% | May 12, 2026 |
| ODTX | CLUSTER | bullish | 7/10 | Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market purchases totaling ~ | May 12, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three top executives at United Therapeutics (CEO, CFO, General Counsel) executed option exercises and sold a portion of | May 12, 2026 |
| MPLT | CLUSTER | neutral | 3/10 | Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market sales over a 7-day w | May 11, 2026 |
| PLSE | CLUSTER | bullish | 7/10 | Two Pulse Biosciences insiders, including CEO Paul LaViolette and director/10% owner Robert Duggan, made open-market pur | May 11, 2026 |
| ODTX | CLUSTER | bullish | 7/10 | Insider cluster at Odyssey Therapeutics shows $20.2M in open-market purchases by directors Li Nan and Chu Shelley at $18 | May 11, 2026 |
| CLRB | CLUSTER | bearish | 6/10 | CLRB's CEO and COO purchased $50K in shares at $2.88, a premium to the heavily dilutive $34.95M offering priced at $2.65 | May 11, 2026 |